Get the Stockscreener App
36.29
1.33%
-0.49
Crispr Therapeutics Ag stock is traded at $36.29, with a volume of 2.08M.
It is down -1.33% in the last 24 hours and down -2.97% over the past month.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
See More
Previous Close:
$36.78
Open:
$36.825
24h Volume:
2.08M
Relative Volume:
1.07
Market Cap:
$3.13B
Revenue:
$170.10M
Net Income/Loss:
$-239.59M
P/E Ratio:
-12.96
EPS:
-2.8
Net Cash Flow:
$-191.20M
1W Performance:
-1.55%
1M Performance:
-2.97%
6M Performance:
-29.08%
1Y Performance:
-32.87%
1-Day Range:
$35.48
$36.95
1-Week Range:
$35.38
$38.12
52-Week Range:
$30.04
$67.88
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Name
Crispr Therapeutics Ag
Sector
Industry
Phone
(617) 315-4600
Address
BAARERSTRASSE 14, ZUG
Compare CRSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
36.29 | 3.18B | 170.10M | -239.59M | -191.20M | -2.80 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-12-25 | Upgrade | TD Cowen | Sell → Hold |
| Feb-03-25 | Initiated | H.C. Wainwright | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| Aug-02-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | Guggenheim | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-27-23 | Initiated | Mizuho | Buy |
| Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
| May-30-23 | Initiated | William Blair | Outperform |
| Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Mar-07-23 | Initiated | Robert W. Baird | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
| Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
| Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-10-20 | Reiterated | Needham | Buy |
| Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Jul-28-20 | Reiterated | Needham | Buy |
| Jul-14-20 | Initiated | SunTrust | Buy |
| Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-01-19 | Initiated | Jefferies | Buy |
| Jul-26-19 | Initiated | Canaccord Genuity | Buy |
| Jun-10-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-14-19 | Initiated | William Blair | Mkt Perform |
| Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
Crispr Therapeutics Ag Stock (CRSP) Latest News
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Insider Naimish Patel Sells 3,932 Shares - MarketBeat
Zacks Research Analysts Raise Earnings Estimates for CRSP - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Capital Market Strategies LLC - MarketBeat
Zacks Research Has Positive Outlook for CRSP Q2 Earnings - Defense World
Two Sigma Advisers LP Buys 28,400 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $71.75 Consensus Target Price from Analysts - MarketBeat
Voloridge Investment Management LLC Reduces Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
ARK Investment Expands Stake in Crispr Therapeutics (CRSP) | CRS - GuruFocus
ARK Investment Expands Stake in Crispr Therapeutics (CRSP) | CRSP Stock News - GuruFocus
Cathie Wood’s ARK Investment buys 294K shares of Crispr Therapeutics today - TipRanks
ARK Investment Increases Stake in Crispr Therapeutics (CRSP) | C - GuruFocus
CRISPR Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Two Sigma Investments LP Grows Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Therapeutics, Clover Health among healthcare stocks to join Russell 3000; INO, SAVA to exit - Seeking Alpha
CRISPR and Cas Genes Market Set to Witness Significant Growth - openPR.com
Cathie Wood’s ARK Investment buys 262K shares of Crispr Therapeutics today - TipRanks
Ameriprise Financial Inc. Acquires 18,412 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Westwood Holdings Group Inc. Raises Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics' (CRSP) "Market Outperform" Rating Reiterated at JMP Securities - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from HC Wainwright - MarketBeat
CRISPR Therapeutics’ SWOT analysis: gene-editing pioneer’s stock faces pivotal year - Investing.com Nigeria
Q2 EPS Estimate for CRISPR Therapeutics Decreased by Analyst - MarketBeat
Rafferty Asset Management LLC Lowers Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Northern Trust Corp Has $10.12 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Cetera Investment Advisers Reduces Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Q2 EPS Estimate for CRISPR Therapeutics Lowered by Analyst - Defense World
Transcript : CRISPR Therapeutics AG Presents at H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025, May-20-2025 04 - marketscreener.com
Transcript : CRISPR Therapeutics AG Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 10 - marketscreener.com
CRSP July 3rd Options Begin Trading - Nasdaq
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Lazard Asset Management LLC - MarketBeat
Ameriprise Financial Inc. Has $8.07 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
(CRSP) Trading Report - news.stocktradersdaily.com
CRISPR Therapeutics AG (CRSP) Strikes $95M Deal with Sirius to Develop Blood Clot Drug - MSN
CRISPR Capacities Expand With New Antiviral Activity - Securities.io
Crispr Therapeutics call volume above normal and directionally bullish - Yahoo Finance
CRSP Stock Outlook: JMP Securities Reiterates Market Outperform Rating | CRSP Stock News - GuruFocus
Truist Financial Remains a Buy on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Crispr Therapeutics AG: Promising Partnership with Sirius Therapeutics Amidst Clinical and Market Uncertainties Warrants Hold Rating - TipRanks
Mizuho Cuts Price Target on CRISPR Therapeutics to $85 From $99, Keeps Outperform Rating - marketscreener.com
Bank of America Corp DE Has $47.69 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Thinks Outside Gene-Editing Box With Sirius Deal - insights.citeline.com
Bullish Options Activity Signals Interest in Crispr Therapeutics (CRSP) | CRSP Stock News - GuruFocus
CRSP: Needham Reiterates Buy Rating with $81 Price Target | CRSP Stock News - GuruFocus
Crispr Therapeutics Ag Stock (CRSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):